Actuate Therapeutics, Inc. (ACTU) - Form 8-K Summary
Business Context and Reporting Period
Actuate Therapeutics, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on September 10, 2025. The filing reports the entry into a material definitive agreement for an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Underwritten public offering of common stock.
- Shares Offered: 2,142,858 shares.
- Over-Allotment Option: Underwriter granted a 30-day option to purchase up to an additional 321,428 shares.
- Offering Price: $7.00 per share.
- Estimated Gross Proceeds: Approximately $15.0 million (excluding underwriting discounts, commissions, and expenses; assuming no over-allotment exercise).
- Underwriter: Lucid Capital Markets, LLC.
- Expected Closing Date: September 11, 2025.
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the company, as this report focuses solely on the capital raising event.
Material Changes and Agreements
The primary material change is the execution of the Underwriting Agreement dated September 10, 2025. Key terms include:
- Lock-Up Agreements: Directors and executive officers have entered into lock-up agreements prohibiting the sale or transfer of securities until December 9, 2025, without prior written consent from the Underwriter.
- Indemnification: The Company agreed to indemnify the Underwriter against certain liabilities under the Securities Act of 1933.
- Registration: The offering was made pursuant to an effective Form S-3 registration statement (No. 333-289988) declared effective on September 8, 2025.
Outlook, Risks, and Management Commentary
Management announced the launch and pricing of the offering via press releases on September 9 and September 10, 2025. The filing notes that the offering is subject to customary closing conditions. No specific forward-looking guidance regarding product development, clinical trials, or future financial performance is provided in this specific document.
Key Facts for Investor Verification
- Verify the final closing of the offering on or after September 11, 2025.
- Confirm whether the underwriter exercises the 30-day over-allotment option for an additional 321,428 shares.
- Review the definitive prospectus supplement (filed September 10, 2025) for details on underwriting discounts and estimated offering expenses to determine net proceeds.
- Monitor the lock-up expiration date of December 9, 2025, for potential selling pressure from insiders.
- Check subsequent filings for the actual use of proceeds and updated cash position.